BIG
ALXN

Bellwether Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Bellwether Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-117
Closed -$14K – 687
2017
Q1 		$14K Sell
117
-831
-88% -$107K 0.04% 415
2016
Q4 		$116K Buy
+948
New +$116K 0.1% 186
2016
Q2 		$172K Buy
+1,477
New +$210K 0.19% 130

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellwether Investment Group's ALXN Position: Q2 2017 in Review

Bellwether Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 117 shares — an estimated $14K sold.

Bellwether Investment Group first reported a position in ALXN in Q2 2016 and held it in 3 quarters. The position peaked at $172K in Q2 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Bellwether Investment Group reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Bellwether Investment Group sold 117 Alexion Pharmaceuticals shares in Q2 2017, an estimated $14K.
  • Bellwether Investment Group first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Bellwether Investment Group's Alexion Pharmaceuticals position peaked at $172K in Q2 2016.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Bellwether Investment Group's 13F filing for Q2 2017, filed 8 Aug 2017.